I graduated as a Medical Doctor from the Medical University of South Africa in 2003. I have more than 12 years’ experience in conducting clinical research in the treatment and prevention of HIV and TB in South Africa, a resource-limited country with a high prevalence of both diseases.
I am a Deputy Director of the Clinical Research Site and am responsible for the TB portfolio as well industry-funded HIV research. I currently serve as a member on the NIH ACTG ARTS TSG, of the Broadly Neutralizing Monoclonal Antibody and Less Frequent-ART Dosing Working Groups of ARTs TSG and the A5381 protocol team. I serve on the South African National Department of Health’s third line antiretroviral treatment approval committee.
At present I am the principal investigator on multiple studies including the ACTG A5381 study, as well as a number of prospective phase II-IV clinical trials with international collaborators including NIH, BMBF, EDCTP, Global TB Alliance, MSF, TB Union and MRC and a number of pharmaceutical industry ART studies. I have chosen a career path in the research of HIV and associated co-infections specifically in the resource-limited setting. I am a dedicated clinician, whose career has developed into a wealth of experience in both protocol implementation and clinical research site management.
Dr Mohammed Rassool
Site Principal Investigator
Clinical HIV Research Unit – Wits Health Consortium South Africa
Email: mrassool@witshealth.co.za
